CL2023001142A1 - Composiciones y métodos para la vacunación contra neisseria gonorrhoeae - Google Patents

Composiciones y métodos para la vacunación contra neisseria gonorrhoeae

Info

Publication number
CL2023001142A1
CL2023001142A1 CL2023001142A CL2023001142A CL2023001142A1 CL 2023001142 A1 CL2023001142 A1 CL 2023001142A1 CL 2023001142 A CL2023001142 A CL 2023001142A CL 2023001142 A CL2023001142 A CL 2023001142A CL 2023001142 A1 CL2023001142 A1 CL 2023001142A1
Authority
CL
Chile
Prior art keywords
compositions
methods
lipoprotein
neisseria gonorrhoeae
vaccination against
Prior art date
Application number
CL2023001142A
Other languages
English (en)
Inventor
Moe Gregory
GIUNTINI Serena
Original Assignee
Omvax Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Omvax Inc filed Critical Omvax Inc
Publication of CL2023001142A1 publication Critical patent/CL2023001142A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/22—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Neisseriaceae (F)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/095—Neisseria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0047—Sonopheresis, i.e. ultrasonically-enhanced transdermal delivery, electroporation of a pharmacologically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/36—Adaptation or attenuation of cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/74—Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/1025—Acyltransferases (2.3)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/523—Bacterial cells; Fungal cells; Protozoal cells expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6018—Lipids, e.g. in lipopeptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/035—Fusion polypeptide containing a localisation/targetting motif containing a signal for targeting to the external surface of a cell, e.g. to the outer membrane of Gram negative bacteria, GPI- anchored eukaryote proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/10—Plasmid DNA
    • C12N2800/101—Plasmid DNA for bacteria
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y203/00—Acyltransferases (2.3)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • Dermatology (AREA)
  • Cell Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Virology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La divulgación se relaciona con composiciones y métodos de uso de las mismas, para vacunas para el tratamiento de una infección gonocócica y/o meningocócica, las cuales comprenden una vesícula de membrana externa nativa (NOMV) derivada de bacterias que contienen una proteína gonocócica que es una lipoproteína o que está modificada para ser una lipoproteína. También tiene relación con cepas meningocócicas que contienen un gen que codifica una proteína gonocócica que es una lipoproteína o que está modificada para ser una lipoproteína.
CL2023001142A 2020-10-23 2023-04-20 Composiciones y métodos para la vacunación contra neisseria gonorrhoeae CL2023001142A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US202063104819P 2020-10-23 2020-10-23

Publications (1)

Publication Number Publication Date
CL2023001142A1 true CL2023001142A1 (es) 2023-12-15

Family

ID=81290088

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2023001142A CL2023001142A1 (es) 2020-10-23 2023-04-20 Composiciones y métodos para la vacunación contra neisseria gonorrhoeae

Country Status (11)

Country Link
US (1) US20230256072A1 (es)
EP (1) EP4232158A1 (es)
JP (1) JP2023546665A (es)
KR (1) KR20230112625A (es)
CN (1) CN116670157A (es)
AU (1) AU2021364838A1 (es)
CA (1) CA3166272A1 (es)
CL (1) CL2023001142A1 (es)
IL (1) IL302286A (es)
MX (1) MX2023004729A (es)
WO (1) WO2022087407A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN117535333B (zh) * 2024-01-04 2024-04-23 南方医科大学皮肤病医院（广东省皮肤病医院、广东省皮肤性病防治中心、中国麻风防治研究中心） 促进淋球菌外膜囊泡分泌的方法、淋球菌敲除株及其制备方法和应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1416352B (zh) * 2000-01-17 2011-05-25 启龙股份公司 含有脑膜炎奈瑟球菌b血清群外膜蛋白质的外膜囊(omv)疫苗
GB0213622D0 (en) * 2002-06-13 2002-07-24 Glaxosmithkline Biolog Sa Vaccine Corporation
US7357932B2 (en) * 2004-06-16 2008-04-15 Center Of Disease Control Department Of Health Surface protein of Neisseria bacteria
TW201221642A (en) * 2010-11-15 2012-06-01 Nat Health Research Institutes Method of producing lipidated polypeptides

Also Published As

Publication number Publication date
WO2022087407A1 (en) 2022-04-28
US20230256072A1 (en) 2023-08-17
JP2023546665A (ja) 2023-11-07
CA3166272A1 (en) 2022-04-28
AU2021364838A9 (en) 2024-05-23
MX2023004729A (es) 2023-06-29
IL302286A (en) 2023-06-01
AU2021364838A1 (en) 2023-06-08
KR20230112625A (ko) 2023-07-27
EP4232158A1 (en) 2023-08-30
CN116670157A (zh) 2023-08-29

Similar Documents

Publication Publication Date Title
CL2023001142A1 (es) Composiciones y métodos para la vacunación contra neisseria gonorrhoeae
ES2663872T3 (es) Composición inmunogénica o vacuna contra infección o enfermedad bacteriana gramnegativa, por ejemplo, por Neisseria
BR112012022688A2 (pt) proteína de fusão, vesícula da membrana externa isolada, polinucleotídeo, composição farmacêutica, vacina, método para tratamento ou prevenção de infecção ou doença por neisseria, uso e método para fabricar uma proteína de fusão
ECSP10010723A (es) Vacuna de vesícula de membrana externa nativa multivalente del meningococo, método para su fabricación y uso
PE20140222A1 (es) Vacunas basadas en omv contra infecciones por burkholderia
RU2014104241A (ru) Способ бездетергентного получения везикул наружной мембраны грамотрицательной бактерии
EA202190184A1 (ru) МОДИФИЦИРОВАННЫЕ ПОЛИПЕПТИДЫ МЕНИНГОКОККОВОГО fHbp
BR112022015626A2 (pt) Composição e métodos de vacinas de mrna contra infecção de novo coronavírus
PE20142115A1 (es) Composiciones de neisseria meningitidis y metodos de las mismas
BR112014031386A2 (pt) vacinas para meningococos do sorogrupo x
ECSP22045408A (es) Bacterias productoras de serotonina
CL2024000709A1 (es) Microorganismos de producción de exopolisacáridos y usos de estos
BR112021019859A2 (pt) Vacinas de circovírus suíno tipo 3 (pcv3) e produção e seus usos
BR112022020298A2 (pt) Vacinas, adjuvantes e métodos para gerar uma resposta imune
WO2023104114A3 (en) Rna formulations and lipids
BR112023002706A2 (pt) Vacinas contra infecções por sars-cov-2
AR123474A1 (es) Vesículas de la membrana externa
BR0316687A (pt) Composição e adjuvante vacinal e método para a obtenção de estruturas cocleares a partir de vesìculas de membrana externa de organismos vivos
AR124923A1 (es) Vacuna recombinante meningocócica b
BR112013010338A2 (pt) composição, métodos para preparar uma composição imunogênica, para adjuvantar uma resposta imune, para eliciar uma resposta imune contra um agente infeccioso, para evitar e/ou reduzir a deposição de amilóide ou doença de alzheimer em um indivíduo, e para tratar/reduzir/melhorar a infecção por uma agente infeccioso, uso de uma proteína, e, kit
CL2014001126A1 (es) Composición farmacéutica útil como vacuna contra bacterias escherichia coli productoras de shigatoxinas (stec), que comprende al menos un antígeno o una proteína de membrana externa inmunogénica o proteína inmunogénica asociada y conservada en cepas stec.
CU24711B1 (es) Composiciones vacunales contra el virus sars-cov-2 basadas en un dímero del dominio de unión al receptor y la vesícula de membrana externa del meningococo b
RU2392326C2 (ru) СПОСОБ ПОЛУЧЕНИЯ L-ТРЕОНИНА С ИСПОЛЬЗОВАНИЕМ БАКТЕРИИ, ПРИНАДЛЕЖАЩЕЙ К РОДУ Escherichia, В КОТОРОЙ ИНАКТИВИРОВАН ОПЕРОН ycbPONME (ОПЕРОН ssuEADCB)
PL430205A1 (pl) Szczepionka, sposób przygotowania szczepionki oraz sposób biotyzacji borówki amerykańskiej
BR112018015255A2 (pt) extrato de streptococcus uberis como um agente imunogênico